Janvier Labs

Janvier Labs

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Janvier Labs is a long-established, privately-held French provider of preclinical research models and services, serving the global biomedical research community. Its core business revolves around breeding and supplying standardized rodent models, with a strong emphasis on genetic stability, animal welfare, and a controlled microbiota to ensure experimental homogeneity. The company has expanded its value proposition to include custom model generation, onsite breeding/management services, and preclinical preparation services, positioning itself as a comprehensive partner for academic and industrial research programs in immunology, oncology, neuroscience, and metabolic diseases.

OncologyImmunologyInfectious DiseasesMetabolic DisordersNeurosciencesCardiovascular diseasesRespiratory diseasesAuto-immune diseases

Technology Platform

Advanced rodent breeding platform ensuring genetic stability, health standardization, a sole microbiota, and animal welfare. Capabilities include genetic engineering for custom model creation, surgical services, and biological sample preparation.

Opportunities

Growing demand for complex humanized and immunodeficient models driven by immuno-oncology and biologic drug development.
Increasing trend of research institutions outsourcing animal breeding and management to specialized providers to reduce costs and complexity.

Risk Factors

Susceptibility to global supply chain and logistical disruptions affecting live animal transport.
Intense competition from larger global players and potential long-term threat from alternative non-animal research technologies.

Competitive Landscape

Operates in a competitive global market with major players like Charles River Laboratories, The Jackson Laboratory, and Taconic Biosciences. Differentiates through its specialized European breeding facility, emphasis on a 'sole microbiota,' and a strong portfolio of immunodeficient and humanized models for translational research.